Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity

Fig. 2

Rheumatoid Arthritis Disease Activity Index total score (RADAI-TS) and Routine Assessment of Patient Index Data 3 (RAPID3) responses. a Adjusted mean least squares (LS) change from baseline in RADAI-TS. b Adjusted mean LS change from baseline in RAPID3. c Percentage of patients reporting improvements greater than or equal to the minimal clinically important difference (MCID) in RADAI. d Percentage of patients reporting improvements greater than or equal to the MCID in RAPID3 (intention-to-treat population, placebo n = 212, CZP n = 851). a p < 0.001 CZP vs. placebo by analysis of covariance; b p < 0.001 CZP vs. placebo by logistic regression. CZP certolizumab pegol, OLE open-label extension, PBO placebo

Back to article page